Table 2.
Outcomes and complications
| Reference | Volume reduction (percent of lesions) | Scar etiology | Method of scar height assessment | Symptoms (percent of patients) | Recurrence rate | Side effects | Follow-up (months) |
|---|---|---|---|---|---|---|---|
| Aggarwal H et al., 2008 [60] | Complete flattening (44 %) | Trauma (30) | N.A. | Symptomatic relief (88.9 %) | 14 % (7 patients) | Ulceration (16 %) | 18 |
| Burn, vaccination, postoperative (10) | Pain (30 %) | ||||||
| (Bleomycin) | Hyperpigmentation (14 %) | ||||||
| No particular histories (10) | |||||||
| Ahuja RB and Chatterjee P, 2013 [61] | Complete flattening [VSS mean value = 0] (100 %) | Foruncle/post-infective (14) | VSS/Caliper | – | 0 % | Pain (3 %) | 6 |
| Surgery (1) | Teleangectasia (9 %) | ||||||
| Burns (4) | Skin atrophy (18 %) | ||||||
| (Triamcinolone) | Trauma (3) | ||||||
| (Verapamil) | |||||||
| Complete flattening [VSS mean value = 0] (100 %) | Foruncle/post-infective (16) | VSS/Caliper | – | 0 % | Pain (3.5 %) | 6 | |
| Surgery (2) | |||||||
| Burns (4) | |||||||
| Trauma (4) | |||||||
| Espana A et al., 2001 [58] | Complete flattening (54 %) | Surgery (5) | N.A. | Itching eliminated (100 %) | 15 % (2 patients) | Hyperpigmentation (15 %) | 13 |
| (Bleomycin) | Spontaneous (3) | ||||||
| Acne (2) | |||||||
| Vaccination (2) | |||||||
| Cut (1) | |||||||
| Griffith BH, 1966 [59] | Complete flattening (51 %) | Infection, surgery, vaccinations, burns, piercing, lacerations, spontaneous, varicella | N.A. | Symptoms eliminated (59 %) or reduced (41 %) | 0 % | Skin atrophy (15 %) | 10 |
| (Triamcinolone) | |||||||
| Gupta S and Kumar B, 2001 [62] | >75 % flattening (58 %) | Burn, acne | N.A. | Symptoms eliminated (100 %) | 0 % | Hypo/depigmentation (100 %) | 9 |
| (Cryosurgery) | |||||||
| Kang N et al., 2006 [63] | No changes in scar volume | Infection (1), assault (1), acne (2), coronary bypass graft (1) | Stereophotogrammetry | – | 100 % | Pain (100 %) | 6 |
| Blistering and skin ulceration (80 %) | |||||||
| Swelling and bruising (100 %) | |||||||
| Pyrexia (20 %) | |||||||
| (Collagenase) | |||||||
| Kiil J, 1977 [64] | Complete flattening (93 %) | Vaccination, surgery, acne, varicella, piercing, spontaneous | N.A. | Itching eliminated (93 %) | 50 % | Acne, menstrual irregularity, fluid retention and striae (percent not reported) | 60 |
| (Triamcinolone) | |||||||
| Kontochristopoulos et al., 2005 [65] | Complete flattening (5 %) | Acne, surgery, folliculitis, vaccination | N.A. | Itching resolution (% not defined) | 47 % | Pain (100 %) | 12 |
| 75 % flattening (40 %) | Skin ulcerations (30 %) | ||||||
| 50 % flattening (40 %) | |||||||
| (5-Fluorouracil) | 25 % flattening (10 %) | Hyperpigmentation (100 %) | |||||
| 0 % flattening (5 %) | |||||||
| Manuskiatti W and Fitzpatrick RE, 2002 [66] | Significant flattening (percent of flattening not reported) | Surgery (sternotomy) | Caliper | – | – | Pain (100 %) | 8 |
| Purpura (20 %) | |||||||
| (5-Fluorouracil) | |||||||
| (Triamcinolone) | Significant flattening (percent of flattening not reported) | Caliper | – | – | Pain (100 %) | 8 | |
| Hypopigmentation (20 %) | |||||||
| Telangiectasia (20 %) | |||||||
| Skin atrophy (10 %) | |||||||
| Margareth Shanthi FX et al., 2008 [67] | Complete flattening [VSS scale] | Acid burns, trauma, surgery, acne, insect bite | VSS/Caliper | – | 0 % | Hypo/hyperpigmentation | 12 |
| Menstrual irregularity | |||||||
| (Triamcinolone) | |||||||
| (Verapamil) | |||||||
| 97 % flattening [VSS scale] | VSS/Caliper | – | 0 % | Profuse sweating | 12 | ||
| Pain | |||||||
| Saray Y and Güleç AT, 2005 [68] | Complete flattening (73.3 %) | Surgery (10), sebaceous cyst (2), vaccination, acne, trauma | Caliper | Complete resolution of pain (67 %) and itching (80 %) | 0 % | Pain (50 %) | 19 |
| >90 % flattening (6.7 %) | Ulceration (100 %) | ||||||
| (Bleomycin) | |||||||
| 75–90 % flattening (13.3 %) | Hyperpigmentation (29 %) | ||||||
| 50–75 % flattening (6.7 %) | Skin atrophy (21 %) |
N.A. not available, VSS Vancouver Scar Scale